Erlonat 150 (Erlotinib) is an anti-cancer drug. It is a drug used to treat non-small cell lung cancer (NSCLC) and also for pancreatic cancer. Especially the Erlonat 150 (Erlotinib) is used for NSCLC with conversions, i.e., mutations in the EGFR (epidermal growth factor receptor). This tablet is prescribed to the victims who have cancer of the lungs which is at a severe developed stage or metastatic lung cancer. This drug is identified as a tyrosine kinase inhibitor and acts by inhibiting the growth of cancerous cells. The usefulness of this drug may vary from person to person, so it is strictly advisable to consult an Oncologist before consuming the medicine.
Title | Description |
---|---|
Dosage Form | Tablet |